Challenges in the pharmacotherapeutic management of the hospitalised patient with Parkinson's disease;Desafíos en el manejo farmacoterapéutico del paciente ingresado con enfermedad de Parkinson

Revista de Neurologia

Volumn 58, Issue 8, 2014, Pages 353-364

  Lertxundi, Unax ^b   Domingo Echaburu, Saioa ^c   Irigoyen, Irati ^b   Isla, Arantxa ^d   Angeles Solinis M ^d   García Moncó, Juan C ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

^b Servicio de Farmacia   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d Vitoria Gasteiz ^*  (Spain)

Author keywords

Antipsychotics; Complications; Hospitalisation; Medication; Parkinson's disease

Indexed keywords

LEVODOPA; NEUROLEPTIC AGENT; ANTIPARKINSON AGENT; GASTROINTESTINAL AGENT;

BRAIN FUNCTION; FOLLOW UP; HOSPITALIZATION; LENGTH OF STAY; NEUROLOGICAL COMPLICATION; PARKINSON DISEASE; PATIENT CARE; REVIEW; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DELIRIUM; DISEASE MANAGEMENT; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; EDUCATION; GASTROINTESTINAL MOTILITY; HALLUCINATIONS; HEALTH CARE PERSONNEL; HICCUP; HUMAN; INAPPROPRIATE PRESCRIBING; MEDICATION ERROR; MORTALITY; PATIENT EDUCATION; PREOPERATIVE CARE; PREVENTION AND CONTROL; PSYCHOLOGY; PSYCHOSES, SUBSTANCE-INDUCED; STATISTICS AND NUMERICAL DATA;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DELIRIUM; DISEASE MANAGEMENT; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HALLUCINATIONS; HEALTH PERSONNEL; HICCUP; HOSPITALIZATION; HUMANS; INAPPROPRIATE PRESCRIBING; MEDICATION ERRORS; PARKINSON DISEASE; PATIENT EDUCATION AS TOPIC; PREOPERATIVE CARE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 84921286271     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5808.2013312     Document Type: Review

References (84)

1. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-35.
2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384-6.
3. Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, et al; National Parkinson Foundation Working Group on Hospitalization in Parkinson's Disease. Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord 2011; 17: 139-45.
4. Vossius C, Nilsen OB, Larsen JP. Parkinson's disease and hospital admissions: frequencies, diagnoses and costs. Acta Neurol Scand 2010; 121: 38-43.
5. Gerlach OH, Broen MP, Van Domburg PH, Vermeij AJ, Weber WE. Deterioration of Parkinson's disease during hospitalization: survey of 684 patients. BMC Neurol 2012; 8: 12-3.
6. Cosentino M, Martignoni E, Michielotto D, Calandrella D, Riboldazzi G, Pacchetti C, et al. Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. BMC Health Serv Res 2005; 5: 26.
7. Domingo-Echaburu S, Lertxundi U, Gonzalo-Olazábal E, Peral-Aguirregoitia J, Peña-Bandrés I. Inappropriate antidopaminergic drug use in Parkinson's disease inpatients. Cur Drug Ther 2012; 7: 164-9.
8. Bhattacharya RK, Dubinsky RM, Lai SM, Dubinsky H. Is there an increased risk of hip fracture in Parkinson's disease? A nationwide inpatient sample. Mov Disord 2012; 15: 1440-3.
9. Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson's disease. Intern Med J 2006; 36: 524-6.
10. Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, et al. Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord 2011; 17: 440-5.
11. Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008; 15: 401-4.
12. Gerlach OH, Winogrodzka A, Weber WE. Clinical problems in the hospitalized Parkinson's disease patient: systematic review. Mov Disord 2011; 26: 197-208.
13. Oguh O, Videnovic A. Inpatient management of Parkinson disease: current challenges and future directions. Neurohospitalist 2012; 2: 28-35.
14. Wood LD, Neumiller JJ, Carlson J, Setter SM, Corbett CF. Challenges of medication management in hospitalized patients with Parkinson's disease. Am J Health Syst Pharm 2010; 67: 2059-63.
15. MacMahon MJ, MacMahon DG. Management of Parkinson's disease in the acute hospital environment. J R Coll Physicians Edinb 2012; 42: 157-62.
16. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-508.
17. Newman EJ, Grosset DG, Kennedy PG. The parkinsonismhyperpyrexia syndrome. Neurocrit Care 2009; 10: 136-40.
18. Brennan KA, Genever RW. Managing Parkinson's disease during surgery. BMJ 2010; 341: c5718.
19. Magdalinou KN, Martin A, Kessel B. Prescribing medications in Parkinson's disease (PD) patients during acute admissions to a District General Hospital. Parkinsonism Relat Disord 2007; 13: 539-40.
20. Luquin MR, Garcia-Ruiz PJ, Martí MJ, Rojo A, Vela L, Grandas FJ, et al. Levodopa en el tratamiento de la enfermedad de Parkinson: mitos y realidades. Rev Neurol 2012; 55: 669-88.
21. Pagonabarraga J, Kulisevsky J. Tratamiento dopaminérgico en la enfermedad de Parkinson: ¿qué puede ofrecer cada familia terapéutica? Rev Neurol 2014; 58: 25-34.
22. Gerlach OH, Broen MP, Weber WE. Motor outcomes during hospitalization in Parkinson's disease patients: a prospective study. Parkinsonism Relat Disord 2013; 19: 737-41.
23. Derry CP, Shah KJ, Caie L, Counsell CE. Medication management in people with Parkinson's disease during surgical admissions. Postgrad Med J 2010; 86: 334-7.
24. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-53.
25. Cortes-Velarde M, Martinez-Rivera M, Menendez-Gonzalez M. Utilización de apomorfina en el paciente con enfermedad de Parkinson. Rev Neurol 2012; 54 (Supl 5): S77-81.
26. Jones SL, Hindle JV. Parkinson's disease in the acute hospital. Clin Med 2011; 11: 84-8.
27. Mariscal A, Medrano IH, Cánovas AA, Lobo E, Loinaz C, Vela L, et al; Sociedad Española de Neurología. Manejo perioperatorio de la enfermedad de Parkinson. Neurología 2012; 27: 46-50.
28. Gallager RG, Thompson MK, Forsyth DR. Getting it right on time? An audit of the administration of Parkinson's disease medications in hospital [abstract]. Mov Disord 2008; 23 (Suppl 1): S338.
29. Parkinson's UK. 'Get it on time' campaign. URL: www.parkinsons.org.uk. [26.04.2013].
30. National Parkinson Foundation. 'Aware in care' campaign. URL: http://www.awareincare.org. [06.05.2013.]
31. Nomenclator Digitalis. URL: http://www.msc.es/ profesionales/farmacia/nomenclatorDI.htm. [06.05.2013].
32. Agencia Española de Medicamentos y Productos Sanitarios. Agonistas dopaminérgicos ergóticos en enfermedad de Parkinson: actualización sobre el riesgo de fibrosis valvular cardíaca. Nota Informativa 2008-11. [06.05.2013].
33. Hou JG, Wu LJ, Moore S, Ward C, York M, Atassi F, et al. Assessment of appropriate medication administration for hospitalized patients with Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 377-81.
34. Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, De Juan A, Martínez-Bengoechea MJ. Antidopaminergic therapy monitoring in Parkinson's disease. Hospital Pharmacy Europe 2007; 3: 76-9.
35. Mulero P, Cortijo-Garcia E, Marco-Llorente J. Abordaje terapéutico de los síntomas no motores de la enfermedad de Parkinson. Rev Neurol 2012; 54 (Supl 5): S89-95.
36. Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord 2010; 16: 553-60.
37. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson's disease psychosis. Arch Neurol 2011; 68: 899-904.
38. Durán-Ferreras E, Chacón JR. Tratamiento de la psicosis en la enfermedad de Parkinson. Rev Neurol 2009; 48: 645-53.
39. Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Enfermedad de Parkinson avanzada: características clínicas y tratamiento. Parte II. Neurología 2013; 28: 558-83.
40. Medrano J. Las bodas de diamante de la clorpromazina. Revista de la Asociación Española de Neuropsiquiatría 2012; 32: 851-66.
41. Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martínez-Bengoechea MJ, García-Moncó JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am J Health Syst Pharm 2008; 65: 414-9.
42. Rudolf J, Grond M, Neveling M, Heiss WD. Clozapineinduced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J Neural Transm 1997; 104: 1305-11.
43. González-Fernández J, Prieto-Albin R, Velasco-Palacios L, Jorge-Roldán S, Cubo-Delgado E. Trastornos digestivos en la enfermedad de Parkinson: disfagia y sialorrea: Rev Neurol 2010; 50 (Supl 2): S51-4.
44. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19: 29-35.
45. Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Longtermfollow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 2006; 29: 215-9.
46. Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 2006; 253: 171-5.
47. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Raterblinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29: 331-7.
48. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27: 153-6.
49. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months duration. Mov Disord 2007; 22: 313-8.
50. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958-63.
51. Zarowitz BJ. Prevalence of antipsychotic use in long-term care residents with Parkinson dementia. Geriatr Nurs 2012; 33: 217-9.
52. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15: 1230-7.
53. Friedman JH. Recommendations on the drug treatment of psychosis in Parkinson's disease. Am J Med 2010; 123: e19.
54. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-7.
55. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimeticinduced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52: 438-45.
56. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17: 1031-5.
57. Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21: 2078-81.
58. Fernández HH, Trieschmann ME, Friedman JH. Aripiprazole for drug induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27: 4-5.
59. Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012; 35: 61-6.
60. Marras C, Gruneir A, Wang X, Fischer H, Gill SS, Herrmann N, et al. Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry 2012; 20: 149-58.
61. Agencia Española de Medicamentos y Productos Sanitarios. Notas informativas sobre Comunicación de Riesgos para Profesionales Sanitarios. Notas Informativas 2004-3, 2004-4 y 2008-19. URL: http://www.aemps.es. [06.05.2013].
62. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
63. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383: 533-40.
64. Boorsma M, Joling KJ, Frijters DH, Ribbe ME, Nijpels G, Van Hout HP. The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homes. Int J Geriatr Psychiatry 2012; 27: 709-15.
65. Flaherty JH, Gonzales JP, Dong B. Antipsychotics in the treatment of delirium in older hospitalized adults: a systematic review. J Am Geriatr Soc 2011; 59 (Suppl 2): S269-76.
66. Gardner D, Murphy A, O'Donnell H, Centorrino F, Baldessarini R. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-93.
67. Hawkins SB, Bucklin M, Muzyk AJ. Quetiapine for the treatment of delirium. J Hosp Med 2013; 8: 215-20.
68. Ruiz MI, Mateos V, Suárez H, Villaverde P. Síndrome confusional agudo (delirium). Guía práctica de diagnóstico y tratamiento. Servicio de Salud del Principado de Asturias. URL: http:// www.asturias.es/portal/site/astursalud/. [18.12.2013].
69. Jost WH. Gastrointestinal dysfunction in Parkinson's disease. J Neurol Sci 2010; 289: 69-73.
70. Seppi K, Weintraub D, Coelho M, Pérez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl 3): S42-80.
71. Scottish Intercollegiate Guidelines Network/British Thoracic Society. Diagnosis and pharmacological management of Parkinson's disease 2010. URL: http://www.sign.ac.uk/ guidelines/fulltext/113/index.html. [10.06.2013].
72. Gálvez-Jiménez N, Lang AE. The perioperative management of Parkinson's disease revisited. Neurol Clin 2004; 22: 367-77.
73. Agencia Española del Medicamento y Productos Sanitarios. Domperidona y riesgo cardíaco. URL: http://www.aemps.gob. es/informa/notasInformativas/medicamentosUsoHumano/ seguridad/2011/NI-MUH_24-2011.htm. [24.05.2012].
74. Lertxundi U, Domingo-Echaburu S, Soraluce A, García M, Ruiz-Osante B, Aguirre C. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard? Curr Drug Saf 2013; 8: 63-8.
75. Ondo WG, Hunter C, Ferrara JM, Mostile G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord 2012; 18: 619-22.
76. Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients-a double blind study. Parkinsonism Relat Disord 1997; 3: 191-3.
77. Ondansetrón: prolongación del intervalo QT del electrocardiograma y nuevas recomendaciones de uso. Nota informativa del Comité de Seguridad de Medicamentos de Uso Humano. Agencia Española del Medicamento. URL: http://www.aemps.gob. es/informa/notasInformativas/medicamentosUsoHumano/ seguridad/2012/NI-MUH_FV_14-2012.htm. [23.05.2013].
78. Messerschmidt KA, Johnson BR, Khan MA. Encephalopathy associated with metoclopramide use in a patient with Parkinson's disease. Am J Health Syst Pharm 2012; 69: 1303-6.
79. Robottom BJ, Shulman LM, Anderson KE, Weiner WJ. Metoclopramide-induced encephalopathy in Parkinson disease. South Med J 2010; 103: 178-80.
80. Miwa H, Kondo T. Hiccups in Parkinson's disease: an overlooked non-motor symptom? Parkinsonism Relat Disord 2010; 16: 249-51.
81. UpToDate. Overview of hiccups. URL: http://www.uptodate. com/contents/overview-of-hiccups. [23.05.2013].
82. Prodigy Guidance. Hiccups. URL: www.cks.library.nhs.uk/ hiccups. [23.05.2013].
83. Stegmeier-Petroianu A, Petroianu GA. Hiccups and dopamine. Am J Health Syst Pharm 2008; 65: 2092-4.
84. Bloomfield K, MacDonald L, Finucane G, Snow B, Roxburgh R. Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital. Intern Med J 2012; 42: e151-6.